MX2022010780A - Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. - Google Patents

Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.

Info

Publication number: MX2022010780A
Authority: MX; Mexico
Prior art keywords: tapentadol; dosage form; prolonged release; phosphoric acid; acid salt
Prior art date: 2020-03-02

Application number

MX2022010780A

Other languages

English (en)

Spanish (es)

Inventor

Ulrike Bertram

Ulrich Reinhold

Christian Grosse

Carmen Hartmann

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-03-02

Filing date

2021-03-01

Publication date

2022-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74701506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022010780(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-03-02 Priority claimed from EP20160419.6A external-priority patent/EP3875077B1/de

2020-03-02 Priority claimed from EP20160420.4A external-priority patent/EP3875079A1/de

2021-03-01 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2022-09-26 Publication of MX2022010780A publication Critical patent/MX2022010780A/es

Links

239000002552 dosage form Substances 0.000 title abstract 3
230000002035 prolonged effect Effects 0.000 title abstract 3
229960005126 tapentadol Drugs 0.000 title abstract 3
-1 tapentadol phosphoric acid salt Chemical class 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 abstract 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 1
235000013334 alcoholic beverage Nutrition 0.000 abstract 1
QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MX2022010780A 2020-03-02 2021-03-01 Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. MX2022010780A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP20160419.6A EP3875077B1 (de)	2020-03-02	2020-03-02	Darreichungsform mit verlängerter freisetzung von tapentadolphosphorsäuresalz
EP20160420.4A EP3875079A1 (de)	2020-03-02	2020-03-02	Darreichungsform mit verlängerter freisetzung von tapentadolphosphorsäuresalz
PCT/EP2021/055025 WO2021175773A1 (en)	2020-03-02	2021-03-01	Dosage form providing prolonged release of tapentadol phosphoric acid salt

Publications (1)

Publication Number	Publication Date
MX2022010780A true MX2022010780A (es)	2022-09-26

Family

ID=74701506

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2022010780A MX2022010780A (es)	2020-03-02	2021-03-01	Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.

Country Status (7)

Country	Link
EP (1)	EP4003318A1 (de)
BR (1)	BR112022017700A2 (de)
CO (1)	CO2022012567A2 (de)
DE (1)	DE202021003994U1 (de)
MX (1)	MX2022010780A (de)
PE (1)	PE20230105A1 (de)
WO (1)	WO2021175773A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20230105A1 (es)	2020-03-02	2023-01-25	Gruenenthal Chemie	Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL88083A (en) *	1987-11-06	1992-11-15	Tanabe Seiyaku Co	Controlled release pharmaceutical dosage form and its preparation
DE4426245A1 (de)	1994-07-23	1996-02-22	Gruenenthal Gmbh	1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es)	2001-10-24	2003-07-26	Gruenenthal Chemie	Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CN1301104C (zh) *	2002-02-21	2007-02-21	大塚制药株式会社	缓释制剂及其制造方法
BRPI0513300B1 (pt)	2004-07-01	2018-11-06	Gruenenthal Gmbh	forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
AU2007309408A1 (en)	2006-10-27	2008-05-02	Janssen Pharmaceutica N.V.	Dry granulated pharmaceutical compositions and methods for producing same
CA2713128C (en)	2008-01-25	2016-04-05	Gruenenthal Gmbh	Pharmaceutical dosage form
RU2673882C1 (ru)	2008-10-30	2018-12-03	Грюненталь Гмбх	Новые и эффективные лекарственные формы тапентадола
CN110015955A (zh)	2010-07-23	2019-07-16	格吕伦塔尔有限公司	3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的盐或共晶体
WO2012051246A1 (en)	2010-10-12	2012-04-19	Ratiopharm Gmbh	Tapentadol hydrobromide and crystalline forms thereof
BR112016000194A8 (pt)	2013-07-12	2019-12-31	Gruenenthal Gmbh	forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
EP3027214A1 (de)	2013-08-02	2016-06-08	ratiopharm GmbH	Zusammensetzung mit tapentadol in gelöster form
EP2942054A1 (de)	2014-05-09	2015-11-11	G.L. Pharma GmbH	Pharmazeutische Formulierung mit langsamer Wirkstoffabgabe
PL3445742T3 (pl)	2016-04-19	2020-05-18	Ratiopharm Gmbh	Krystaliczny fosforan tapentadolu
ES2963929T3 (es)	2017-05-29	2024-04-03	Gruenenthal Gmbh	Forma farmacéutica oral multipartículas que proporciona liberación prolongada de tapentadol
PE20230105A1 (es)	2020-03-02	2023-01-25	Gruenenthal Chemie	Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol

2021
- 2021-03-01 PE PE2022001894A patent/PE20230105A1/es unknown
- 2021-03-01 EP EP21707730.4A patent/EP4003318A1/de not_active Withdrawn
- 2021-03-01 BR BR112022017700A patent/BR112022017700A2/pt unknown
- 2021-03-01 MX MX2022010780A patent/MX2022010780A/es unknown
- 2021-03-01 WO PCT/EP2021/055025 patent/WO2021175773A1/en not_active Ceased
- 2021-03-01 DE DE202021003994.5U patent/DE202021003994U1/de active Active
2022
- 2022-09-02 CO CONC2022/0012567A patent/CO2022012567A2/es unknown

Also Published As

Publication number	Publication date
CO2022012567A2 (es)	2022-09-09
WO2021175773A1 (en)	2021-09-10
PE20230105A1 (es)	2023-01-25
DE202021003994U1 (de)	2022-04-12
BR112022017700A2 (pt)	2023-01-17
EP4003318A1 (de)	2022-06-01

Similar Documents

Publication	Publication Date	Title
BR112015002421A2 (pt)	2017-07-04	composição farmacêutica ou nutracêutica com características de liberação sustentada e com resistência contra a influência do etanol
JP5902628B2 (ja)	2016-04-13	相乗的抗ウイルス組成物及びその使用
Li et al.	2015	Autophagy regulators as potential cancer therapeutic agents: a review
MX2008010155A (es)	2008-10-17	Composiciones virucidales que contienen metal y sus usos.
MX2021013139A (es)	2021-11-25	Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
BR112017019343A2 (pt)	2018-05-02	uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
MX2016002999A (es)	2016-06-02	Composiciones de neisseria meningitidis y sus metodos.
MX2022010780A (es)	2022-09-26	Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.
HRP20201703T1 (hr)	2020-12-25	Liječenje kokcidioze intramuskularnim triazinskim pripravcima
US20070110676A1 (en)	2007-05-17	Compositions useful for prevention and treatment of common cold and influenza-like symptoms
JP2016510343A5 (de)	2017-03-16
SI2646011T1 (en)	2018-01-31	Procedures for reducing disturbance or compulsive overeating
MX2013003523A (es)	2013-05-22	Composicion farmaceutica de dosis baja.
ZA202106768B (en)	2025-01-29	Triamterene or nolatrexed for use in the treatment of phenylketonuria
CO2023008265A2 (es)	2023-06-30	Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación
CN111315374A (zh)	2020-06-19	合成的赖氨酸类似物和模拟物的用于抗病毒用途的方法和组合物
ZA202400915B (en)	2025-05-28	Pharmaceutical composition and use thereof
MX2017013643A (es)	2018-03-08	Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
Yoo et al.	2012	FRI0143 A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis
WO2011119649A3 (en)	2012-02-23	Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
PH12023553121A1 (en)	2024-02-12	Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
MX2025014331A (es)	2026-01-07	Composicion farmaceutica para prevenir o tratar enfermedades infecciosas por coronavirus que comprende un oligomero de peptido-acido nucleico permeable a celulas como ingrediente activo
MX2019001738A (es)	2019-05-09	Formulacion de efedrina y sus derivados resistente a la manipulacion.
US20220061315A1 (en)	2022-03-03	Persistent sanitizer
Shah et al.	2011	Clinical efficacy of a novel new injectable diclofenac formulation designed for intradeltoid use in post-operative pain management